The global digital therapeutics market size was USD 6.36 billion in 2023, calculated at USD 7.88 billion in 2024 and is projected to surpass around USD 56.76 billion by 2034, expanding at a double digit CAGR of 21.83% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. DataSources
2.3. Assumptions& Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Market SWOT Analysis
5.1. Covid-19: Digital Therapeutics Industry Impact
5.2. Digital Therapeutics Business Impact Assessment: Covid-19
5.2.1. Distribution Channel Challenges/Disruption
5.2.2. Market Trends and Digital Therapeutics Opportunities in the COVID-19 Landscape
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Digital Therapeutics Manufacturers to deal with Covid-19 Pandemic Scenario
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing Penetration of Digital Healthcare Applications & Platforms
6.1.1.2. Rapid Adoption of Smartphones & Tablets
6.1.2. Market Restraints
6.1.2.1. Lack of Proper Monetization Strategy
6.1.3. Market Opportunities
6.1.3.1. Implementation of Machine Learning and Artificial Intelligence in Digital Therapeutics Platforms
7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Digital Therapeutics Market Revenue by Manufacturer
7.1.1.2. Digital Therapeutics Market Revenue Market Share by Manufacturer
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Capacity Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Digital Therapeutics Market, by Product Type, 2024-2034
8.1.1. Device
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Software
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Digital Therapeutics Market, by Sales Channel, 2024-2034
9.1.1. Business-to-Consumer (B2C)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.1.2. Caregiver
9.1.1.3. Patient
9.1.2. Business-to-Business (B2B)
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.2.2. Healthcare Provider
9.1.2.3. Employer
9.1.2.4. Others
10.1. Digital Therapeutics Market, by Application, 2024-2034
10.1.1. Obesity
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Central Nervous System (CNS) Disease
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Gastrointestinal Disorder (GID)
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Cardiovascular Disease (CVD)
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Smoking Cessation
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Respiratory Disease
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue Forecast by Product Type (2021-2034)
11.1.2. Market Revenue Forecast by Sales Channel (2021-2034)
11.1.3. Market Revenue Forecast by Application (2021-2034)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2021-2034)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2021-2034)
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type (2021-2034)
11.2.2. Market Revenue Forecast by Sales Channel (2021-2034)
11.2.3. Market Revenue Forecast by Application (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2021-2034)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2021-2034)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type (2021-2034)
11.3.2. Market Revenue Forecast by Sales Channel (2021-2034)
11.3.3. Market Revenue Forecast by Application (2021-2034)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2021-2034)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2021-2034)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type (2021-2034)
11.4.2. Market Revenue Forecast by Sales Channel (2021-2034)
11.4.3. Market Revenue Forecast by Application (2021-2034)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2021-2034)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2021-2034)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type (2021-2034)
11.5.2. Market Revenue Forecast by Sales Channel (2021-2034)
11.5.3. Market Revenue Forecast by Application (2021-2034)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2021-2034)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2021-2034)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2021-2034)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2021-2034)
12.1. Fitbit Health Solutions
12.1.1. Company Overview, Business Information, Manufacturing Area
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price and Gross Margin
12.1.4. Recent Developments and Strategies
12.2. 2MORROW, Inc.
12.2.1. Company Overview, Business Information, Manufacturing Area
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price and Gross Margin
12.2.4. Recent Developments and Strategies
12.3. Medtronic Plc.
12.3.1. Company Overview, Business Information, Manufacturing Area
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price and Gross Margin
12.3.4. Recent Developments and Strategies
12.4. Livongo Health, Inc.
12.4.1. Company Overview, Business Information, Manufacturing Area
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price and Gross Margin
12.4.4. Recent Developments and Strategies
12.5. Pear Therapeutics, Inc.
12.5.1. Company Overview, Business Information, Manufacturing Area
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price and Gross Margin
12.5.4. Recent Developments and Strategies
12.6. Omada Health, Inc.
12.6.1. Company Overview, Business Information, Manufacturing Area
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price and Gross Margin
12.6.4. Recent Developments and Strategies
12.7. Resmed, Inc. (Propeller Health)
12.7.1. Company Overview, Business Information, Manufacturing Area
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price and Gross Margin
12.7.4. Recent Developments and Strategies
12.8. Proteus Digital Health, Inc.
12.8.1. Company Overview, Business Information, Manufacturing Area
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price and Gross Margin
12.8.4. Recent Developments and Strategies
12.9. Welldoc, Inc.
12.9.1. Company Overview, Business Information, Manufacturing Area
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price and Gross Margin
12.9.4. Recent Developments and Strategies
12.10. Voluntis, Inc.
12.10.1. Company Overview, Business Information, Manufacturing Area
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price and Gross Margin
12.10.4. Recent Developments and Strategies
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client